Gilead Sciences, Inc. (Nasdaq: GILD) today announced the acquisition of all outstanding shares of XinThera, a privately held biotech company in San Diego. The acquisition complements Gilead’s existing clinical development priorities by adding additional pipeline assets for well-validated targets in oncology and .
San Diego, CA (PRWEB) September 08, 2022 XinThera, Inc., a drug discovery company focused on building a small molecule oncology and immunology pipeline,